In this context, signaling pathway of adhesion protein HSP90α/β has been shown to give proliferative advantage to MDS MSCs in patients with advanced-stage MDS, [126] being a potential therapeutic target in MDS. The gene discussed is HSP90AA1; the disease is myelodysplastic syndrome.